1. Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes.
- Author
-
Naumenko, Victor, Rajwani, Jahanara, Turk, Madison, Zhang, Chunfen, Tse, Mandy, Davis, Rachelle P., Kim, Daesun, Rakic, Andrea, Dastidar, Himika, Van, Shinia, Mah, Laura K., Kaul, Esha K., Chekhonin, Vladimir P., Mahoney, Douglas J., and Jenne, Craig N.
- Subjects
MONOCYTES ,ONCOLYTIC virotherapy ,VESICULAR stomatitis ,TUMOR growth ,TUMOR microenvironment ,NEUTROPHILS - Abstract
There is debate in the field of oncolytic virus (OV) therapy, whether a single viral dose, or multiple administrations, is better for tumor control. Using intravital microscopy, we describe the fate of vesicular stomatitis virus (VSV) delivered systemically as a first or a second dose. Following primary administration, VSV binds to the endothelium, initiates tumor infection and activates a proinflammatory response. This initial OV dose induces neutrophil migration into the tumor and limits viral replication. OV administered as a second dose fails to infect the tumor and is captured by intravascular monocytes. Despite a lack of direct infection, this second viral dose, in a monocyte-dependent fashion, enhances and sustains infection by the first viral dose, promotes CD8 T cell recruitment, delays tumor growth and improves survival in multi-dosing OV therapy. Thus, repeated VSV dosing engages monocytes to post-condition the tumor microenvironment for improved infection and anticancer T cell responses. Understanding the complex interactions between the subsequent viral doses is crucial for improving the efficiency of OV therapy and virus-based vaccines. A secondary (but not primary) dose of the oncolytic virus, VSV, is captured by monocytes and promotes CD8 + T cell recruitment, thereby revealing a mechanism underlying the clinical benefit of repeat dosing in oncolytic virus therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF